Piramal Enterprises appoints new executive director
This article was originally published in Scrip
Indian company Piramal Enterprises, parent company of Piramal Healthcare, has appointed Murari Rajan executive director with responsibility for mergers, acquisitions and corporate development. Mr Rajan joins Piramal with over 15 years' experience in the financial services industry; prior to the appointment he was a consultant at Egon Zehnder International in the Financial Services Practice in New York. Mr Rajan will lead the strategy and M&A efforts for both Piramal Healthcare and Piramal Glass Limited, as well as hold a position on the investment committee of IndiaReit and India Ventures.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).